Impact of selective platelet inhibition in reducing cardiovascular risk - role of vorapaxar
Judy WM Cheng Department of Pharmacy Practice, MCPHS University, Boston, MA, USA Abstract: This article reviews the pharmacology, clinical efficacy, and safety of vorapaxar in reducing cardiovascular risk. Vorapaxar is a tricyclic himbacine-derived reversible inhibitor of platelet surface protease a...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2016-06-01
|
| Series: | Vascular Health and Risk Management |
| Subjects: | |
| Online Access: | https://www.dovepress.com/impact-of-selective-platelet-inhibition-in-reducing-cardiovascular-ris-peer-reviewed-article-VHRM |